By year-end 2028, submit new drug application evaluating cemsidomide and dexamethasone for potential accelerated approval in fourth line or later. In Q2 2026, initiate the Phase 1b trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback